GWS
NVO

Greykasell Wealth Strategies’s Novo Nordisk NVO Stock Holding History

Greykasell Wealth Strategies’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.4K Hold
2,269
– – 0.03% 207
2025
Q4 		$115K Buy
2,269
+112
+5% +$5.73K 0.05% 177
2025
Q3 		$120K Hold
2,157
– – 0.05% 165
2025
Q2 		$149K Hold
2,157
– – 0.07% 144
2025
Q1 		$150K Buy
+2,157
New +$178K 0.08% 134

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Greykasell Wealth Strategies's NVO Position: Q1 2026 in Review

Greykasell Wealth Strategies held its Novo Nordisk (NVO) position steady in Q1 2026 at 2,269 shares worth $83.4K. The position accounts for 0.03% of the portfolio, ranked #207.

Greykasell Wealth Strategies first reported a position in NVO in Q1 2025 and has held it in 5 quarters since. The position peaked at $150K in Q1 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Greykasell Wealth Strategies held 2,269 shares of Novo Nordisk worth $83.4K as of Q1 2026.
  • Greykasell Wealth Strategies left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up 0.03% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #207 holding.
  • Greykasell Wealth Strategies first reported a position in Novo Nordisk in Q1 2025 and has held it in 5 quarters since.
  • Greykasell Wealth Strategies's Novo Nordisk position peaked at $150K in Q1 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.